Candida albicans proteins associated with virulence and hyphal formation and uses thereof
OwnerEkkehard Leberer, David Y. Thomasinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to Candida albicans proteins, such as CaCla4p, Cst20p, CaCdc42p and CaBem1p, associated with virulence and hyphal formation and uses thereof, such as to design screening tests for inhibitors for the treatment of pathogenic fungi infections and/or inflammation conditions. The invention also relates to an in vitro screening test for compounds to inhibit the biological activity of at least one protein selected from the group consisting of CaCla4p, Cst20p, CaCdc42p and CaBem1p, which comprises: a) at least one of said proteins; and b) means to monitor the biological activity of said at least one protein; thereby compounds are tested for their inhibiting potential.
Claims7
An isolated gene encoding a protein of Candida albicans selected from the group consisting of CaCla4p (SEQ ID NO:8), Cst20p (SEQ ID NO:
- 6), CaCdc42p (SEQ ID NO:
- 10) and CaBem1p (SEQ ID NO:
- 12).
An isolated Candida albicans protein selected from the group consisting of CaCla4p (SEQ ID NO:8), Cst20p (SEQ ID NO:
- 6), CaCdc42p (SEQ ID NO:
- 10) and CaBem1p (SEQ ID NO:
- 12).
An in vitro screening assay for identifying a potential anti-fungal compound, said assay comprising the steps of:
- a) combining at least one protein selected from the group consisting of CaCla4p (SEQ ID NO:8), Cst20p (SEQ ID NO:
- 6), CaCdc42p (SEQ ID NO:
- 10) and CaBem1p (SEQ ID NO:
- 12) with a target that interacts with said protein in a protein/target interaction;
- b) adding a test compound to the protein/target mixture;
- and
- c) measuring the protein/target interaction, wherein an interruption of the protein/target interaction indicates that said test compound is a potential inhibitor.
Dependencies are inferred from the claim text.